Weight-loss patients taking Zepbound forced to switch to Wegovy after drop in coverage

Weight-loss patients taking Zepbound forced to switch to Wegovy after drop in coverage

Patients report concerns about side effects and effectiveness after being told to transition to Wegovy

Some patients taking GLP-1 drugs for weight loss have been forced to switch to a different medication due to a change in insurance coverage. (iStock)

Wegovy is an injectable prescription weight-loss medicine made by the Danish company Novo Nordisk. (Michael Siluk/UCG/Universal Images Group via Getty Images)

Zepbound — along with its counterpart diabetes medication, Mounjaro — is made by Eli Lilly, which is headquartered in Indianapolis. (iStock)

A recent study found that tirzepatide achieved greater weight loss than semaglutide, with participants shedding about 50 pounds (20.2% of their body weight). (iStock)

"Switching drugs is not always seamless; dosing must often be re-titrated, and side effects can re-emerge," one expert said. (iStock)